Form 8-K NEUROCRINE BIOSCIENCES For: Oct 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- US stock futures slip ahead of inflation report
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil gains as stalled US-Iran talks trump supply recovery
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Wells Fargo raises oil price targets citing ongoing supply risks
Neurocrine Biosciences (NBIX) Misses Q3 EPS by 15c
October 29, 2015 4:15 PM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q3 EPS of ($0.40), $0.15 worse than the analyst estimate of ($0.25).
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
... More